Evommune (EVMN) Corporate Presentation summary

Addressing chronic inflammation and unmet medical needs

• Chronic inflammation contributes to 3 out of 5 deaths globally and imposes an annual direct healthcare cost of at least $90B, with current therapies lacking efficacy and safety for many patients.

• The mission is to address critical gaps in care for immune-mediated diseases by strategically selecting mechanisms with high probability of success and maintaining a steady cadence of new clinical programs.

Pipeline overview and clinical milestones

• Two main programs in Phase 2: EVO756 (oral MRGPRX2 antagonist) for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301 (IL-18BP fusion protein) for AD.

• Three Phase 2 clinical data readouts are expected in 2026: EVO756 in CSU (H1), EVO756 in AD (H2), and EVO301 in AD (H1).

• Additional preclinical programs are advancing toward clinical proof-of-concept in a broad range of inflammatory diseases.

EVO756 clinical data and development

• EVO756 demonstrated robust clinical activity and safety in Phase 1 and 2 trials, with 30% complete response rate at 4 weeks in chronic inducible urticaria and well-tolerated dosing.

• Pharmacokinetic modeling supports both QD and BID dosing regimens, with strong target engagement and dose-proportional pharmacokinetics.

• Phase 2b trials in CSU and AD are dose-ranging, double-blind, and placebo-controlled, with topline data expected in 2026.